[1] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1): 73-84. [2] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol, 2017, 67(4): 862-873. [3] Fan J, Wei L, Zhuang H, et al. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). J Dig Dis, 2019, 20(4): 163-173. [4] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol, 2013, 10(6): 330-344. [5] Lu Z, He B, Chen Z, et al. Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway. BMC Immunol, 2020, 21(1): 28. [6] Wang Y, Zhou X, Zhao D, et al. Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes. PLoS One, 2020, 15(5): e0232630. [7] Phimmachanh M, Han JZR, O'donnell YEI, et al. Histone deacetylases and histone deacetylase inhibitors in neuroblastoma. Front Cell Dev Biol, 2020, 8: 578770. [8] Sun B, Jia Y, Hong J, et al. Sodium butyrate ameliorates high-fat-diet-induced non-alcoholic fatty liver disease through peroxisome proliferator-activated receptor alpha-mediated activation of beta oxidation and suppression of inflammation. J Agric Food Chem, 2018, 66(29): 7633-7642. [9] Cheng Z, Wen Y, Liang B, et al. Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD. Mol Omics, 2019, 15(1): 50-58. [10] Du J, Ding X, Zhang X, et al. Berberine attenuate staphylococcal enterotoxin B-mediated acute liver injury via regulating HDAC expression. AMB Express, 2018, 8(1): 158. [11] Kalaiarasi A, Anusha C, Sankar R, et al. Plant isoquinoline alkaloid berberine exhibits chromatin remodeling by modulation of histone deacetylase to induce growth arrest and apoptosis in the A549 cell line. J Agric Food Chem, 2016, 64(50): 9542-9550. [12] Fruhbeck G, Gomez-Ambrosi J, Rodriguez A, et al. Novel protective role of kallistatin in obesity by limiting adipose tissue low grade inflammation and oxidative stress. Metabolism, 2018, 87: 123-135. [13] Ji W, Shi H, Shen H, et al. Mechanism of KLF4 protection against acute liver injury via inhibition of apelin signaling. Oxid Med Cell Longev, 2019, 2019: 6140360. [14] Wang C, Zhang M, Wu J, et al. The Effect and mechanism of TLR9/KLF4 in FFA-induced adipocyte inflammation. Mediators Inflamm, 2018, 2018: 6313484. [15] Hu L, Yu Y, Huang H, et al. Epigenetic regulation of interleukin 6 by histone acetylation in macrophages and its role in paraquat-induced pulmonary fibrosis. Front Immunol, 2016, 7: 696. |